Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5926 AL 5940

Silencing of CDK5 as potential therapy for Alzheimer's disease

López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP.

Rev Neurosci. 2011;22(2):143-52. doi: 10.1515/RNS.2011.015.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11.

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]

Delrieu J, Piau A, Vellas B.

Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13.

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease

Nie Q, Du XG, Geng MY.

Acta Pharmacol Sin. 2011 May;32(5):545-51. doi: 10.1038/aps.2011.14. Epub 2011 Apr 18.

Assessing family caregiver skill in managing behavioral symptoms of Alzheimer's disease

Farran CJ, Fogg LG, McCann JJ, Etkin C, Dong X, Barnes LL.

Aging Ment Health. 2011 May;15(4):510-21. doi: 10.1080/13607863.2010.536140.

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A.

Expert Opin Biol Ther. 2011 Jun;11(6):679-86. doi: 10.1517/14712598.2011.579099. Epub 2011 Apr 19.

Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors

Mancini F, De Simone A, Andrisano V.

Anal Bioanal Chem. 2011 Jun;400(7):1979-96. doi: 10.1007/s00216-011-4963-x. Epub 2011 Apr 20.

Solanezumab for Alzheimer's disease

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20.

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes

Imbimbo BP, Giardina GA.

Curr Top Med Chem. 2011;11(12):1555-70. doi: 10.2174/156802611795860942.

γ-secretase substrates and their implications for drug development in Alzheimer's disease

Lleó A, Saura CA.

Curr Top Med Chem. 2011;11(12):1513-27. doi: 10.2174/156802611795861004.

Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease

Britton GB, Smith MA, Perry G, Sambamurti K, Jagannatha Rao KS.

J Alzheimers Dis. 2011;24 Suppl 2:1-2. doi: 10.3233/JAD-2011-110021.

[Do medicines with aim to anti-Alzheimer favor the arisen of epileptic crisis? Discussion about 3 clinical cases]

Roy M, Castro-Lionard K, Crawford-Achour E, Desseigne N, Beyens MN, Guy C, Imler D, Cornillon D.

Therapie. 2011 May-Jun;66(3):291-3. doi: 10.2515/therapie/2011038.

Medical foods for Alzheimer's disease

Shah RC.

Drugs Aging. 2011 Jun 1;28(6):421-8. doi: 10.2165/11587380-000000000-00000.

Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study

Martínez Lozano MD, Guzmán Quilo C; Primeras Consultas Study Group.

Expert Rev Neurother. 2011 May;11(5):657-63. doi: 10.1586/ern.11.45.

Guest editorial: Time for a change

Keady J, Swarbrick C.

Int J Older People Nurs. 2011 Jun;6(2):81-2. doi: 10.1111/j.1748-3743.2011.00271.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias